Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Clinical trial NCT03425461 · TERMINATED

Trial details

NCT number: NCT03425461
Sponsor: Jonsson Comprehensive Cancer Center
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Melanoma Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7

Start date: 2018-06-14
Primary completion: 2021-03-04
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.